[Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].
A 59-year-old woman received eight cycles of R-CHOP for diffuse large B-cell lymphoma from July, 2004. Pretreatment HBV serological tests were positive, however, the transaminases were within normal limits, and she remained asymptomatic. Lamivudine (LAM) was administered orally from the start of R-CHOP. HBV-DNA levels gradually decreased and were not detected until December, 2004. LAM was administered until 3 months after the end of chemotherapy, with the entire treatment lasting less than 1 year. Two months after the cessation of treatment, she was re-admitted for general malaise. A liver function test revealed severe abnormalities, and HBVDNA levels were increased. Clinically, she was experiencing acute hepatitis due to HBV reactivation. She was then treated with LAM and interferon-beta immediately. Her HBV-DNA levels soon decreased, and liver function improved.
Ono
Kaoru
K
Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine.
Iyama
Satoshi
S
Matsunaga
Takuya
T
Sato
Tsutomu
T
Sato
Yasushi
Y
Okuda
Toshinori
T
Takada
Kohichi
K
Kawano
Yutaka
Y
Hayashi
Tsuyoshi
T
Miyanishi
Koji
K
Sagawa
Tamotsu
T
Kobune
Masayoshi
M
Takimoto
Rishu
R
Kato
Junji
J
Niitsu
Yoshiro
Y
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000821:virology*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000821:virology; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects*
D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D004279:DNA, Viral; D019259:Lamivudine; D000069283:Rituximab; D014750:Vincristine; D016899:Interferon-beta; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone